MOG and myeloid sarcoma: Antimyelin oligodendrocyte glycoprotein (MOG) antibodies, anti-MBP antibodies, and antibodies to the ATP-sensitive inward rectifying potassium channel KIR4.1 have been also reported as useful clinical markers of MS [22, 23].